SG10201500597YA - Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome - Google Patents

Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Info

Publication number
SG10201500597YA
SG10201500597YA SG10201500597YA SG10201500597YA SG10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA
Authority
SG
Singapore
Prior art keywords
dengue
fever
infections
antibody
mediated
Prior art date
Application number
SG10201500597YA
Other languages
English (en)
Inventor
Neil M Bodie
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of SG10201500597YA publication Critical patent/SG10201500597YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/116Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201500597YA 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome SG10201500597YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
SG10201500597YA true SG10201500597YA (en) 2015-04-29

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201500597YA SG10201500597YA (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Country Status (13)

Country Link
US (1) US8815813B2 (https=)
EP (1) EP2320924B1 (https=)
JP (1) JP5806112B2 (https=)
CN (1) CN102159231B (https=)
AU (2) AU2009270805B2 (https=)
BR (1) BRPI0915968B1 (https=)
CA (1) CA2731218A1 (https=)
HR (1) HRP20150620T1 (https=)
IL (1) IL210717A (https=)
MX (1) MX2011000647A (https=)
MY (1) MY160699A (https=)
SG (1) SG10201500597YA (https=)
WO (1) WO2010009380A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005221187B2 (en) 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
MX2011000647A (es) 2008-07-18 2011-09-29 Trinity Therapeutics Inc Metodos para el tratamiento de infecciones por fiebre de dengue mediadas por el sistema inmunitario e intensificacion dependiente de anticuerpos de infecciones por fiebre de dengue, incluyendo fiebre hemorragica de dengue y sindrome de choque de deng
EP3236986A4 (en) * 2014-12-22 2018-10-24 Middle Tennessee State University Methods for treating immune-mediated viral infections
ES3058443T3 (es) * 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) * 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) * 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) * 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US6319897B1 (en) * 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
WO2000015214A1 (en) * 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
US6818611B1 (en) * 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2002038592A2 (de) 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
DE60318065T2 (de) 2002-06-07 2008-11-20 Trillium Therapeutics Inc., Toronto Fcyriia-transgenes tiermodell für autoimmunkrankheit
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
AU2005221187B2 (en) * 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
ES2388501T3 (es) 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
CN101277714B (zh) * 2005-09-06 2013-01-30 三一治疗公司 治疗免疫介导的神经疾病的方法
EP1960427B1 (en) 2005-12-13 2011-02-23 SuppreMol GmbH Multimeric fc receptor polypeptides
US20120021988A1 (en) * 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
MX2011000647A (es) 2008-07-18 2011-09-29 Trinity Therapeutics Inc Metodos para el tratamiento de infecciones por fiebre de dengue mediadas por el sistema inmunitario e intensificacion dependiente de anticuerpos de infecciones por fiebre de dengue, incluyendo fiebre hemorragica de dengue y sindrome de choque de deng

Also Published As

Publication number Publication date
WO2010009380A9 (en) 2010-04-08
AU2009270805B2 (en) 2016-11-03
CA2731218A1 (en) 2010-01-21
BRPI0915968A2 (pt) 2020-08-18
EP2320924B1 (en) 2015-03-11
US20110218157A1 (en) 2011-09-08
CN102159231A (zh) 2011-08-17
WO2010009380A2 (en) 2010-01-21
AU2017200760A1 (en) 2017-03-02
JP5806112B2 (ja) 2015-11-10
MY160699A (en) 2017-03-15
IL210717A0 (en) 2011-03-31
MX2011000647A (es) 2011-09-29
BRPI0915968B1 (pt) 2021-11-23
US8815813B2 (en) 2014-08-26
HK1158066A1 (en) 2012-07-13
EP2320924A1 (en) 2011-05-18
JP2011528665A (ja) 2011-11-24
HRP20150620T1 (xx) 2015-09-25
AU2009270805A1 (en) 2010-01-21
IL210717A (en) 2017-07-31
EP2320924A4 (en) 2012-07-25
CN102159231B (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
GB2471806B (en) Compositions and methods for treating viral infections
LT2083811T (lt) Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai
IL210717A0 (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
EP2124921A4 (en) SULFONYL SEMI-CARBAZIDES, CARBONYL SEMI-CARBAZIDS, SEMI-CARBAZIDS AND UREA, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING ARENAVIRUS-ASSOCIATED INFECTIONS
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
IL185056A0 (en) Compositions and methods for treating or preventing flaviviridae infections
EP2344155A4 (en) COMPOSITION AND METHOD FOR TREATING A DRY EYE
IL207170A0 (en) Methods of treating viral infections
PT1951633T (pt) Composição para vidro de elevado desempenho, fibras de vidro de elevado desempenho e artigos feitos a partir das mesmas
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
ZA200905990B (en) Recombinant antibodies for treatment of respriratory syncytial virus infections
ZA201008215B (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
IL195272A0 (en) Methods and compositions for the treatment of viral infections
EP2060949A4 (en) RADIATION-SENSITIVE COMPOSITION AND PROCESS FOR PRODUCING A LOW-MOLECULAR COMPOUND FOR USE THEREIN
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
DK2158281T3 (da) Farvepigmenteret laksammensætning med høj dækkeevne, forøget ridsefasthed, og let-at-rengøre egenskaber
BRPI0920892A2 (pt) Composição de bebida e processo de redução de degradação de monatina.
IL210682A0 (en) Glass hardening methods and compositions
ZA201109492B (en) Compositions comprising finafloxacin and methods for treating ophthalmic,otic,or nasal infections
ZA201100779B (en) Composition for reinforcing hollow glass and protecting same from scratching,corresponding treatment methods and resulting treated hollow glass
EP1937235A4 (en) METHOD FOR TREATING VIRUS INFECTIONS WITH POLYAMINE ANALOGUE
EP2086560A4 (en) METHODS OF TREATING EPIPHORA
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
IL196825A0 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers